DexCom SVP Sells $754,834 in Stock (DXCM)
DexCom (NASDAQ:DXCM) SVP Jeffrey Moy sold 16,663 shares of the company’s stock in a transaction dated Tuesday, August 26th. The shares were sold at an average price of $45.30, for a total value of $754,833.90. Following the completion of the sale, the senior vice president now directly owns 97,916 shares in the company, valued at approximately $4,435,595. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
A number of research firms have recently commented on DXCM. Analysts at Zacks reiterated a “neutral” rating on shares of DexCom in a research note on Friday, August 8th. They now have a $46.00 price target on the stock. Separately, analysts at Raymond James reiterated an “outperform” rating on shares of DexCom in a research note on Thursday, August 7th. They now have a $46.00 price target on the stock, up previously from $44.00. Finally, analysts at Canaccord Genuity raised their price target on shares of DexCom from $40.00 to $48.00 in a research note on Thursday, August 7th. They now have a “buy” rating on the stock. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and seven have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $41.00.
Shares of DexCom (NASDAQ:DXCM) traded down 1.99% on Thursday, hitting $44.28. The stock had a trading volume of 448,339 shares. DexCom has a 52 week low of $25.49 and a 52 week high of $49.83. The stock’s 50-day moving average is $40.61 and its 200-day moving average is $39.11. The company’s market cap is $3.342 billion.
DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Wednesday, August 6th. The company reported ($0.09) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.10) by $0.01. The company had revenue of $58.80 million for the quarter, compared to the consensus estimate of $52.45 million. During the same quarter last year, the company posted ($0.14) earnings per share. DexCom’s revenue was up 64.2% compared to the same quarter last year. On average, analysts predict that DexCom will post $-0.32 earnings per share for the current fiscal year.
DexCom, Inc (NASDAQ:DXCM) is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients.
Receive News & Ratings for DexCom Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.